[go: up one dir, main page]

MX2018002446A - Compuestos heterociclicos fusionados como moduladores s1p. - Google Patents

Compuestos heterociclicos fusionados como moduladores s1p.

Info

Publication number
MX2018002446A
MX2018002446A MX2018002446A MX2018002446A MX2018002446A MX 2018002446 A MX2018002446 A MX 2018002446A MX 2018002446 A MX2018002446 A MX 2018002446A MX 2018002446 A MX2018002446 A MX 2018002446A MX 2018002446 A MX2018002446 A MX 2018002446A
Authority
MX
Mexico
Prior art keywords
modulators
fusioned
compounds
heterociclical
heterociclical compounds
Prior art date
Application number
MX2018002446A
Other languages
English (en)
Other versions
MX376700B (es
Inventor
Amberg Wilhelm
Ochse Michael
Mezler Mario
Hornberger Wilfried
Hutchins Charles
turner Sean
Lange Udo
Van Der Kam Elizabeth
Van Bergeijk Jeroen
Oellien Frank
Walleser Patrick
Geneste Herve
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018002446A publication Critical patent/MX2018002446A/es
Publication of MX376700B publication Critical patent/MX376700B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos heterocíclicos como moduladores S1P, composiciones farmacéuticas que comprenden tales compuestos, y a usos de los mismos en el tratamiento, alivio o prevención de enfermedades o trastornos mediados por un receptor S1P.
MX2018002446A 2015-08-28 2016-08-26 Compuestos heterociclicos fusionados como moduladores s1p. MX376700B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/088447 2015-08-28
US201562242558P 2015-10-16 2015-10-16
PCT/EP2016/070225 WO2017036978A1 (en) 2015-08-28 2016-08-26 Fused heterocyclic compounds as s1p modulators

Publications (2)

Publication Number Publication Date
MX2018002446A true MX2018002446A (es) 2019-01-10
MX376700B MX376700B (es) 2025-03-07

Family

ID=56801561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002446A MX376700B (es) 2015-08-28 2016-08-26 Compuestos heterociclicos fusionados como moduladores s1p.

Country Status (10)

Country Link
US (1) US10556907B2 (es)
EP (1) EP3341369A1 (es)
JP (1) JP2018525429A (es)
CN (1) CN108368107B (es)
AU (1) AU2016314973B2 (es)
BR (1) BR112018003776A2 (es)
CA (1) CA2996741A1 (es)
MX (1) MX376700B (es)
TW (1) TW201720822A (es)
WO (1) WO2017036978A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234488A1 (en) * 2017-06-23 2018-12-27 Basf Se Substituted cyclopropyl derivatives
EP3883935A4 (en) 2018-11-20 2022-08-10 Georgetown University COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMA STORAGE DISEASES
US20220296620A1 (en) * 2019-08-07 2022-09-22 National University Corporation Tokyo Medical And Dental University Agent for preventing or treating mild cognitive impairment
CN112505213B (zh) * 2019-12-19 2022-04-08 金陵药业股份有限公司 一种清热养阴活血祛瘀口服液成分检测方法
JP7307282B2 (ja) * 2020-03-04 2023-07-11 ヒーリオイースト ファーマシューティカル カンパニー リミテッド ベンゾ２－アザスピロ［４．４］ノナン系化合物及びその使用
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
CN119776509A (zh) * 2023-10-08 2025-04-08 华东师范大学 Ndufa10基因和S1pr4基因突变在肌病诊断、预测和治疗中的用途
US20250281500A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease
US20250281497A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of seizure disorders
WO2025188976A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of neurodegenerative disorders
WO2025188977A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of addiction and insomnia
WO2025188974A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768720B2 (en) * 1999-04-01 2004-01-08 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
MXPA05012459A (es) * 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresoras.
JP4728962B2 (ja) * 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
ES2527117T3 (es) * 2003-08-29 2015-01-20 Ono Pharmaceutical Co., Ltd. Compuesto capaz de unirse a receptor SIP y uso farmacéutico del mismo
CN101407471A (zh) * 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
DE102004020908A1 (de) 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
EP1998620B1 (en) * 2006-03-10 2011-01-12 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
MX2009010060A (es) * 2007-03-21 2010-01-20 Epix Pharm Inc Compuestos moduladores del receptor de esfingosin-1-fosfato y uso de los mismos.
GB0910691D0 (en) * 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
TWI522361B (zh) * 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
AR084515A1 (es) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
EP2650284A1 (en) * 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
EP3083573B1 (en) * 2013-12-18 2024-08-07 Merck Sharp & Dohme LLC Inhibitors of the renal outer medullary potassium channel

Also Published As

Publication number Publication date
US10556907B2 (en) 2020-02-11
JP2018525429A (ja) 2018-09-06
CA2996741A1 (en) 2017-03-09
MX376700B (es) 2025-03-07
TW201720822A (zh) 2017-06-16
AU2016314973A1 (en) 2018-03-08
CN108368107B (zh) 2021-11-26
AU2016314973B2 (en) 2020-10-15
CN108368107A (zh) 2018-08-03
EP3341369A1 (en) 2018-07-04
BR112018003776A2 (pt) 2018-09-25
WO2017036978A1 (en) 2017-03-09
US20170057966A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2016010296A (es) Compuestos farmaceutios.
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
GT201500190A (es) Lactamas fusionadas de arilo y heteroarilo
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
CL2016003212A1 (es) Derivados de indolín-2-ona o pirrolo-piridín-2-ona.
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
MX2017014375A (es) Moduladores del ccr2.
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas

Legal Events

Date Code Title Description
FG Grant or registration